BeyondSpring
BYSI

$1.97

5.07%

Market Cap: 79.2M

About: BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.

Employees: 36

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

5,333% more call options, than puts

Call options by funds: $326K | Put options by funds: $6K

328% more capital invested

Capital invested by funds: $4.91M [Q4 2023] → $21M (+$16.1M) [Q1 2024]

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

5% more funds holding

Funds holding: 20 [Q4 2023] → 21 (+1) [Q1 2024]

1.03% more ownership

Funds ownership: 14.05% [Q4 2023] → 15.09% (+1.03%) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BYSI.

See Analyst Rankings

Financial journalist opinion

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtual Research and Development (R&D) Day to discuss its lead asset Plinabulin, a dendritic cell (DC) maturation agent, in drug combinations to potentially address the current unmet medical needs in cancer indications where patients failed prior PD-1/PD-L1 inhibitors, as well as updates for SEED Therapeutics which focuses on target protein degradation (TPD) platform for innovative molecular glue drug discovery on May 15, 2024.

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET.

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring Files 2023 Annual Report on Form 20-F

FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”) on April 29, 2024. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.

BeyondSpring Files 2023 Annual Report on Form 20-F

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring's lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350].

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). In the Letter, the staff of Nasdaq notified the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(2), because it has not timely filed its Form 6-K for the period ended June 30, 2023 (the “Filing”).

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on December 14, 2023, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's ordinary shares (the “Ordinary Shares”) was below $1.00 per share for 31 consecutive business days. The notification letter does not result in the immediate delisting of the Company's Ordinary Shares and has no current immediate effect on the listing or trading of the Company's Ordinary Shares on Nasdaq.

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

See News Rankings